| 0 (0%) | 12-27 00:24 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 18.64 | 1-year : | 21.77 |
| Resists | First : | 15.96 | Second : | 18.64 |
| Pivot price | 14.26  |
|||
| Supports | First : | 13.85 | Second : | 12.56 |
| MAs | MA(5) : | 14.85 |
MA(20) : | 14.03 |
| MA(100) : | 15.84 |
MA(250) : | 0 | |
| MACD | MACD : | 0 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 52.7 |
D(3) : | 63.1 |
| RSI | RSI(14): 49.7 |
|||
| 52-week | High : | 25 | Low : | 12.56 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ PLSE ] has closed below upper band by 43.7%. Bollinger Bands are 28.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 14.82 - 14.89 | 14.89 - 14.96 |
| Low: | 14.07 - 14.15 | 14.15 - 14.24 |
| Close: | 14.23 - 14.38 | 14.38 - 14.52 |
Fri, 26 Dec 2025
Is PLSE stock attractive for growth ETFs - Candlestick Trading Patterns & Low Risk Investment Plans - bollywoodhelpline.com
Fri, 26 Dec 2025
Understanding the Setup: (PLSE) and Scalable Risk - Stock Traders Daily
Thu, 25 Dec 2025
Pulse Biosciences (PLSE): Valuation Check After FDA IDE Approval for nPulse Cardiac Ablation Trial - simplywall.st
Tue, 23 Dec 2025
Why Pulse Biosciences (PLSE) Is Up 8.0% After FDA Clears Pivotal Atrial Fibrillation Trial - Sahm
Sun, 21 Dec 2025
Pulse Biosciences (NASDAQ:PLSE) Is In A Good Position To Deliver On Growth Plans - Sahm
Sat, 20 Dec 2025
Pulse Biosciences (PLSE): Valuation Check After FDA IDE Approval for nPulse Cardiac Ablation Trial - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
|
|
|
Sector:
|
|
|
Industry:
|
|
| Shares Out | 0 (M) |
| Shares Float | 68 (M) |
| Held by Insiders | 1.757e+007 (%) |
| Held by Institutions | 73.9 (%) |
| Shares Short | 2,370 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -7.785e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -23 % |
| Return on Assets (ttm) | 682.5 % |
| Return on Equity (ttm) | -49 % |
| Qtrly Rev. Growth | 86000 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | -48.33 |
| EBITDA (p.s.) | -107222 |
| Qtrly Earnings Growth | -1.2 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -49 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.3 |
| Price to Cash Flow | 18.91 |
| Dividend | 0 |
| Forward Dividend | 2.46e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|